Global Electroporation Instruments Market 20202024 Evolving Opportunities...
The electroporation instruments market is poised to grow by USD 72.67 million during 20202024 during the forecast period. Request free sample pagesThis press release features multimedia. View the full...
View ArticlePregnancy and rates of Crohn&x2019;s . . . and other stories
Childbearing and Crohns diseaseAn analysis of data from a Norwegian patient register finds that pregnancy leads to a reduction in the risk of Crohns disease. Among women whose youngest child was...
View ArticleGossamer Bio Announces Data Presentations at the Congress of the European...
Gossamer Bio Inc. Nasdaq GOSS a clinicalstage biopharmaceutical company focused on discovering acquiring developing and commercializing therapeutics in the disease areas of immunology inflammation and...
View ArticleGossamer Bio Announces Data Presentations at the Congress of the European...
Gossamer Bio Inc. Nasdaq GOSS a clinicalstage biopharmaceutical company focused on discovering acquiring developing and commercializing therapeutics in the disease areas of immunology inf...
View ArticleNew Phase 3b Interim Data from STARDUST Study Show TwoThirds of Patients with...
First Study to Explore a TreattoTarget Strategy in Crohns Disease using Endoscopy to Guide Dose AdjustmentFirst Study to Evaluate Intestinal Ultrasound Monitoring in an Interventional SettingThe...
View ArticleMultinational Inflammatory Bowel Disease Survey Uncovers Striking Differences...
Survey reveals important differences in how patients and physicians define disease remission and the importance of remission as a clinical goal1The high prevalence of corticosteroid therapy currently...
View ArticleInterim data shows Stelara promise in Crohns
Interim data from the Phase IIIb STARDUST study showed that 79 of patients with moderately to severely active Crohn’s disease CD achieved clinical response and 67 were in clinical remission.
View ArticleInterim data shows Stelara promise in Chrons
Interim data from the Phase IIIb STARDUST study showed that 79 of patients with moderately to severely active Crohn’s disease CD achieved clinical response and 67 were in clinical remission.
View ArticleJAK1 Inhibitor Promising for Refractory Crohn's
>MedPage Today The JAK1 inhibitor upadacitinib Rinvoq was superior to placebo in inducing endoscopic remission in refractory Crohn's disease CD patients the phase II randomized CELEST trial...
View ArticleJanssen's Stelara Sees Positive Results in Crohn's Disease Study
Janssen Pharmaceutical said 79 of patients in a latestage trial showed a clinical response to the medication and 67 were in clinical remission.
View ArticleJohnson & Johnson reports positive results for Stelara using "treattotarget"...
Johnson & Johnson reports positive results for Stelara using "treattotarget" approach in Phase III Crohn's disease trial httpswww.firstwordpharma.comnode1700915tsid28&regionid6...
View ArticleInvestigational Subcutaneous Formulation of Vedolizumab Achieves Clinical...
New data from the VISIBLE 2 trial presented at the 15th Congress of the European Crohns and Colitis Organisation ECCOTakeda Pharmaceutical Company Limited TSE4502NYSETAK Takeda today annou
View ArticleCelltrion Healthcare showcases positive 1year results for novel subcutaneous...
Switching and longterm results from a randomised controlled trial RCT showed that the subcutaneous SC formulation of infliximab was comparable to the intravenous IV formulation of CTP13 biosimilar...
View ArticleHuman medicines European public assessment report EPAR Amsparity adalimumab...
Human medicines European public assessment report EPAR Amsparity adalimumab Arthritis RheumatoidArthritis Juvenile RheumatoidPsoriasisArthritis PsoriaticSpondylitis AnkylosingUveitisColitis...
View ArticleJanssen's Stelara Sees Positive Results in Crohn's Disease Study...
Janssen's Stelara Sees Positive Results in Crohn's Disease Study httpdlvr.itRQ3Fg3 pic.twitter.com2k0nnJheeG
View ArticleNew phase 3b interim data from STARDUST study show majority patients with...
Intestinal ultrasound IUS responses were assessed and were detected as early as week 4.2 Week 16 data digital oral presentation or DOP 13 and IUS response data DOP The post New phase 3b interim data...
View ArticleStrong Phase 3 data for Takeda's Entyvio combo in moderate to severe Crohn's...
Takeda has shared positive new Phase 3 data on a subcutaneous formulation of its gutselective biologic Entyvio vedolizumab as a maintenance therapy for moderately to severely active Crohn's disease CD...
View ArticleStrong Phase 3 data for Takeda's subcutaneous Entyvio in moderate to severe...
Takeda has shared positive new Phase 3 data on a subcutaneous formulation of its gutselective biologic Entyvio vedolizumab as a maintenance therapy for moderately to severely active Crohn's disease CD...
View ArticleStrong Phase 3 data for Takeda's Entyvio combo in moderate to severe Crohns...
Strong Phase 3 data for Takeda's Entyvio combo in moderate to severe Crohns disease httpbit.ly2HxxlOU pharma pic.twitter.comZPlTgFfhsw
View ArticleCelltrion showcases positive oneyear results for subcutaneous formulation of...
Results presented at The European Crohn&8217;s and Colitis Organisation ECCO 2020 annual congress in Vienna Austria demonstrated that the SC formulation of CTP13 was comparable to the IV The post...
View Article